Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease
Objective: To evaluate the impact of fecal microbiome transplant (FMT) on disease progression as a secondary outcome of a safety study using PRIM-DJ2727 in Parkinson's…The influence of culture on the relationship between subjective and objective assessments of dyskinesia severity.
Objective: To explore the relationship and rate of agreement between patient and clinician evaluation of dyskinesia severity and impact on function across multiple cultures. Background:…Novel approach to MDS-UPDRS monitoring in clinical trials: Longitudinal Item Response Theory Models
Objective: Using the unique advantages of Item Response Theory (IRT), we developed unidimensional and multidimensional models to investigate non-tremor and tremor MDS-UPDRS Part 3 changes…Reliability and Validity of the Greek Translation of the Scale for Assessment and Rating Ataxia in Ataxic Children
Objective: Translation and Cross-cultural adaptation of the Scale for Assessment and Rating Ataxia (SARA) in Greek ataxic pediatric population. Background: Ataxia in the pediatric population…Effects of levodopa on cognitive functions in Parkinson’s disease
Objective: To assess the dynamics of cognitive functions (CF) under the influence of levodopa in PD patients Background: Our research is devoted to an urgent problem-the…MDS Translation Program for MDS-UPDRS, UDysRS, and MDS-NMS
Objective: To summarize the status of the ongoing MDS-sponsored translation programs for non-English versions of the MDS-UPDRS, UDysRS, and MDS-NMS. Background: The MDS-UPDRS, UDysRS, and…Cognitive-driven ADL impairment as a predictor for PDD
Objective: To evaluate whether Parkinson’s disease (PD) patients with mild activity of daily living (ADL) impairment are at higher risk for developing dementia (PDD). Background:…Maximising UPDRS information while minimising assessment time
Objective: The gold standard for measuring disease severity in PD (Parkinson’s Disease) is the MDS-UPDRS (Movement Disorder Society - Unified PD Rating Scale) [1]. However,…Prognostic Modeling of Parkinson’s Disease Progression Using Early Longitudinal Patterns of Change
Objective: To develop a prognostic model using multiple longitudinal measures to predict temporal clinical progression in early PD. Background: Predicting time to Parkinson’s disease (PD)…Development of the Parkinson’s Disease Medication Adherence Scale (PD-MAS)
Objective: To implement the first 3 phases of the scale development process that will create the PD-MAS. Background: Drug therapy is a central strategy in…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 32
- Next Page »